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Population pharmacokinetics (PPK) tries to
find a model, which describes a drug course in the
patientís body and investigates statistical distribu-
tion of parameters of that model in the population
under study. The purpose of this analysis may be
purely utilitarian (e.g. in therapeutic drug monitor-
ing, TDM) or cognitive (as one may wish to do with
the data gathered during clinical observation).
The statistical theory makes parameter estimation
possible also in the case of sparse data, i.e. when the
number of measured drug concentrations from a
given subject is less than or not much greater than
the number of pharmacokinetic (PK) model param-
eters. This is of great advantage, because it makes
routine clinical data usable for population analysis.
However, an estimation of the model for sparse data
is a very difficult statistical and computational task.
A number of approaches to this problem have been
developed. Table 1 enumerates the most important
of them along with the appropriate computer pro-
grams.
Each of these methods constitutes significantly
distinct approach to the PPK problem, both in the
aspect of the assumptions as well as numeric algo-
rithms applied. The first three approaches have their
origins in the maximum likelihood method, the very
fundamental statistical principle. 
The NONMEM program searches for a likeli-
hood function maximum by means of numerical
algorithms. Next two methods search for likelihood
maximizing parameters without necessity of explic-
it calculation of likelihood function. These methods
differ in the way they express the parameter distri-
bution. In the parametric EM, the parametric family
of distributions (like normal or log-normal) is
assumed. On the other hand, the non-parametric EM
replaces continuous statistical distributions by their
discrete approximations (3, 5). This allows for a
greater flexibility in a description of parameter dis-
tributions. 
The principle of the MCMC approach is quite
different. It makes use of statistical experiment in
order to determine empirical distribution of each
measurable population characteristic under investi-
gation (6, 7). 
It was of interest to investigate, for the
approaches considered:
● to which degree estimated parameters agree
with their true values, 
● to evaluate the efficacy of the
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approaches/programs and the agreement of the
results between them.
The first point was the subject of previous sim-
ulation studies (8, 9), in which the true parameter
values where known and it was possible to control a
fulfillment of the assumptions.
In the present study, a focus is on the real clin-
ical data. Not only PK parameters true values remain
unknown, but also one does not know to which




Patient records with evidence of CBZ intoxica-
tion from the Clinic of Toxicology, Jagiellonian
University, Collegium Medicum were used. There
were selected patients belonging to the following
groups:
■ epileptic patients (E),
■ patients with alcoholism with alcohol detect-
ed in their blood at the time of admission to the hos-
pital (A),
■ patients with alcoholism with no alcohol in
blood at the time of admission (N).
Each patient had CBZ concentration determined at
the time of admission, and the additional 0-4 con-
centrations measured in the course of therapy
(Figure 1). Thus, the data are sparse. It is unknown
what CBZ form was taken. In addition, the supposi-
tions on the time and dose of CBZ administration
are only rough approximations.
Pharmacokinetic and statistical model
The clinical observations made in the course of
routine medical care suggest the CBZ pharmacoki-
netics for therapeutic doses may be described by the
one-compartment model with the first order elimi-
nation (10). Due to the lack of data on the drug form
administered, both zero and first order absorption
had to be considered. In the case of the zero order
absorption ñ which may be adequate for the pro-
longed release drug forms ñ the time of absorption
was chosen as a pharmacokinetic parameter. For the
first order absorption, the related PK parameter is
the first order absorption constant, . There is also a
parameter  in both models, which combines the lag
time with the correction for the time of administra-
tion.
The volume of distribution could not be select-
ed as the model parameter because of the uncertain-
ty of the drug form and its dose. Therefore, the
parameter is a mixture of the volume of distribution,
the fraction absorbed and the correction of dose to
its true value. The clearance is the fourth parameter
of the model. Unfortunately, important patient data,
such as body weight or height, were missed. It made
investigation of regression models for clearance and
parameter unfeasible.
The Gaussian distribution was assumed for
parameter in the studied populations. For the other
parameters log-normal distribution was assumed.
The intraindividual variability of the measured con-
centrations was assumed to be normally distributed
with a heteroschedastic variance model (the constant
coefficient of variance model).
RESULTS AND DISCUSSION
Computational issues
The computations with the NONMEM program
were not fully successful for any group and model.
Despite the estimates of the PK parameters and their
variances were obtained, the estimation of the results
accuracy failed and the software notified the numer-
ical issues. For a certain initial data, the program
unexpectedly exited without any message. The
choice of proper initial parameter values was the
main difficulty in the computations with NONMEM.
Thermo Kinetica was less sensitive on initial
parameters, but the stop criterion for iterations
appeared to be too liberal: using the final parameter
values as initial values for the next run sometimes
led to significantly different final results and each
run the results were different.
The simulation studies yielded promising
results for the NPAG program (8). Unfortunately, it
Table 1. Methods and software for population pharmacokinetic analysis of sparse data.
Method Program Authors/originators
Nonlinear mixed-effect modelling NONMEM (1) Sheiner L., Beal S. (UCSF)
Expectation maximization (EM) Thermo Kinetica (2) MentrÈ F., Gomeni R.
Nonparametric EM NPAG (3) Jelliffe R., Schumitzky A., Leary R. (USC)
Markov Chain Monte Carlo (MCMC) WinBugs/PKBugs (4) Lunn D.J., St Maryís Hospital, London 
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performed worse in the present study. Only the test
version (beta) was available to the authors. It is not
known, if the program is still under development.
No significant dependency of WinBugs/
PKBugs results on the (reasonably chosen) initial
parameter guesses was found. The observed statisti-
cal, post-hoc distributions of PK parameters provide
a certain insight into the reasons of computational
issues encountered with other programs. Figure 2
shows probability density plots for the zero-order
absorption model parameters. The distributions for
clearance and  parameter are in the agreement with
the assumed log-normal distribution. On the other
hand, the shape of other parameters distribution
appears irregular and it changes with the number of
iterations. This indicates the estimates of absorption
time and of  parameter are subject to a greater uncer-
tainty. Nevertheless, the plot suggests short absorp-
tion times, not exceeding 2 hours. This is in agree-
ment with the patientsí profiles (Figure 1), where,
for a majority of subjects, the absorption phase is
poorly seen. It may thus be presumed that the pro-
longed release drug forms were rarely used.
Consequently, the use of the first order absorption
model as a population model is better motivated.
The results of such modelling with a PKBugs pro-
gram are shown in Figure 3. The clearance and
parameter distributions are again regular and similar
to those from the previous model. Also remaining
two parameters behavior is similar to that previous-
ly observed. Therefore, the first order absorption
constant and  parameter cannot be estimated with a
satisfactory accuracy.
In the study described, the comparison of the
absorption and elimination parameters is of special
interest. Table 2 compiles estimates of these param-
eters obtained for the subsequent programs and both
absorption models. Despite significant differences
for the same data sets were obtained, their mutual
relations between groups are, in general, consistent.
Besides one exception, for each method and absorp-
tion model the lowest clearance values were
obtained for the A group and the highest values of
that parameter for the N group. Contrary, the first
order absorption constant seems to reach the highest
values in the A group.
The above suppositions require a thorough sta-
tistical reasoning before they could be expressed as
Table 2. Clearance and absorption parameter estimates for studied programs and both absorption models. 
First-order absorption Patient group1
Program E (n = 76)2 N (n = 35) A (n = 46)
NONMEM 5.75 ± 8.523 8.45 ± 18.44 2.17 ± 2.14
Clearance Thermo Kinetica 4.06 ± 0.70 4.64 ± 0.74 2.17 ± 1.14
[L h-1] NPAG 4.76 ± 2.81 5.54 ± 3.10 4.41 ± 2.60
PKBugs 5.28 ± 4.71 6.21 ± 6.04 3.70 ± 3.72
NONMEM 0.70 ± 0.007 8.42 ± 0.08 7.70 ± 0.07
Absorption Thermo Kinetica 3.58 ± 0.70 4.60 ± 1.55 14.56 ± 0.94
constant ka [h
-1] NPAG 3.74 ± 3.93 4.61 ± 2.73 5.60 ± 8.26
PKBugs 11.06 ± 4.20 8.90 ± 5.96 28.21 ± 20.29
Zero-order absorption
NONMEM 6.16 ± 3.90 2.22 ± 0.84 1.83 ± 0.88
Clearance Thermo Kinetica 4.43 ± 1.02 4.92 ± 0.94 2.31 ± 1.27
[L h-1] NPAG 3.33 ± 2.34 5.46 ± 2.92 5.11 ± 3.32
PKBugs 5.29 ± 4.72 5.77 ± 5.56 3.61 ± 3.51
NONMEM 0.30 ± 0.19 0.17 ± 0.15 0.18 ± 0.15
Absorption time Thermo Kinetica 2.68 ± 0.97 1.93 ± 0.57 1.94 ± 0.49
[h] NPAG 5.22 ± 2.99 5.98 ± 4.06 9.93 ± 3.68
PKBugs 0.72 ± 0.24 0.53 ± 0.78 0.28 ± 0.13  
1 E ñ epilepsy; N ñ alcoholism, no alcohol in blood; A ñ alcoholism, alcohol detected in blood.
2 Number of subjects in group.
3 Population parameter value ± its standard deviation in population.
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Figure 1. Spaghetti plot of CBZ concentrations in three patient groups. E ñ epilepsy; N ñ alcoholism, no alcohol in blood; A ñ alcoholism,
alcohol detected in blood.
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Figure 2. Empirical probability density of PK parameters for the one compartment model with zero order absorption: a ñ log of clearance,
b ñ log of V parameter, c ñ log of absorption time, d ñ t0 parameter, e and f ñ same as c and d, respectively, but obtained for the random
sample twice as large as for a-d (600000 vs 300000).
Figure 3. Empirical probability density of PK parameters for the one compartment model with first order absorption: a ñ log of clearance,
b ñ log of V parameter, c ñ log of absorption rate constant, d ñ t0 parameter.
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credible conclusions. This might be a subject of a
separate study.
CONCLUSIONS
The computational issues noticed are not neces-
sarily a proof of malfunctioning of the given approach
or bugs in a software. Rather, they indicate the assump-
tions of these approaches do not hold. It is possible, not
all the model parameters are identifiable (11). For the
majority of profiles the absorption phase is poorly
noticeable, therefore one could not expect reliable esti-
mates for parameters related to this process.
Simultaneous use of different approaches to
population pharmacokinetics is recommended,
because it provides better inspection into possible
imperfections of population pharmacokinetic model.
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